Skip to main content
SpringerLink
Log in

Secondary Prevention After Cardioembolic Stroke

  • Chapter
Ischemic Stroke Therapeutics

  • 2263 Accesses

Abstract

Cardiac causes of ischemic stroke usually lead to severe neurological deficits from large intracranial artery occlusion compared to small vessel ischemic stroke. The most common cause of cardioembolic stroke is nonvalvular atrial fibrillation (AF), which has an increasing incidence with age. Other less common causes of cardioembolic stroke include myocardial infarction, left ventricular thrombus, reduced left ventricular ejection fraction, valvular abnormalities, and endocarditis. Patent foramen ovale (PFO) is a common finding on echocardiograms in patients with and without stroke (up to 20 % of the population), and a controversial source of cryptogenic stroke. AF stroke trials demonstrate that anticoagulation is superior to antiplatelet therapy in terms of ischemic stroke and systemic embolism prevention. Recently, warfarin has been compared with a number of drugs with different mechanisms of anticoagulation, namely direct thrombin (Factor II) inhibitors and Factor Xa inhibitors, which are collectively referred to as the novel or new oral anticoagulants (NOAC). Overall, the NOACs were found to be at least equally effective in reducing ischemic stroke with less intracranial bleeding risk. NOACs are attractive because of warfarin’s narrow therapeutic index, requirement for frequent blood monitoring, multiple drug interactions, and a higher rate of intracranial bleeding as compared to NOACs in randomized trials. The best way to prevent cardioembolic stroke remains early detection and treatment of AF in eligible patients, and treating the underlying stroke mechanism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol. 1989;46(7):727–43.

    Google Scholar 

  2. Bogousslavsky J, Cachin C, Regli F, Despland PA, Van Melle G, Kappenberger L. Cardiac sources of embolism and cerebral infarction – clinical consequences and vascular concomitants: the Lausanne Stroke Registry. Neurology. 1991;41(6):855–9.

    Article  CAS  PubMed  Google Scholar 

  3. Sila CA. Cardioembolic stroke. Neurological therapeutics: principles and practice. New York, NY: Martin Dunitz; 2003. p. 450–7.

    Google Scholar 

  4. Petty GW, Brown Jr RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke. 1999;30(12):2513–6.

    Article  CAS  PubMed  Google Scholar 

  5. Ferro JM. Cardioembolic stroke: an update. Lancet Neurol. 2003;2(3):177–88.

    Article  PubMed  Google Scholar 

  6. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation. 2012;127(1):e6–245.

    Article  PubMed  Google Scholar 

  7. Caplan LR, Hier DB, D’Cruz I. Cerebral embolism in the Michael Reese Stroke Registry. Stroke. 1983;14(4):530–6.

    Article  CAS  PubMed  Google Scholar 

  8. Arboix A, Oliveres M, Massons J, Pujades R, Garcia-Eroles L. Early differentiation of cardioembolic from atherothrombotic cerebral infarction: a multivariate analysis. Eur J Neurol. 1999;6(6):677–83.

    Article  CAS  PubMed  Google Scholar 

  9. Caplan L. Posterior circulation ischemia: then, now, and tomorrow. The Thomas Willis Lecture-2000. Stroke. 2000;31(8):2011–23.

    Article  CAS  PubMed  Google Scholar 

  10. Bogousslavsky J, Regli F, Maeder P, Meuli R, Nader J. The etiology of posterior circulation infarcts: a prospective study using magnetic resonance imaging and magnetic resonance angiography. Neurology. 1993;43(8):1528–33.

    Article  CAS  PubMed  Google Scholar 

  11. Caplan LR, Wityk RJ, Glass TA, Tapia J, Pazdera L, Chang H-M, et al. New England Medical Center posterior circulation registry. Ann Neurol. 2004;56(3):389–98.

    Article  PubMed  Google Scholar 

  12. Glass TA, Hennessey PM, Pazdera L, Chang H-M, Wityk RJ, Dewitt LD, et al. Outcome at 30 days in the New England Medical Center Posterior Circulation Registry. Arch Neurol. 2002;59(3):369–76.

    Article  PubMed  Google Scholar 

  13. Schonewille WJ, Wijman CAC, Michel P, Algra A, Kappelle LJ, BASICS Study Group. The basilar artery international cooperation study (BASICS). Int J Stroke. 2007;2(3):220–3.

    Article  PubMed  Google Scholar 

  14. Pessin MS, Lathi ES, Cohen MB, Kwan ES, Hedges 3rd TR, Caplan LR. Clinical features and mechanism of occipital infarction. Ann Neurol. 1987;21(3):290–9.

    Article  CAS  PubMed  Google Scholar 

  15. Yamamoto Y, Georgiadis AL, Chang HM, Caplan LR. Posterior cerebral artery territory infarcts in the New England Medical Center Posterior Circulation Registry. Arch Neurol. 1999;56(7):824–32.

    Article  CAS  PubMed  Google Scholar 

  16. Ramirez-Lassepas M, Cipolle RJ, Bjork RJ, Kowitz J, Snyder BD, Weber JC, et al. Can embolic stroke be diagnosed on the basis of neurologic clinical criteria? Arch Neurol. 1987;44(1):87–9.

    Article  CAS  PubMed  Google Scholar 

  17. Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology. 1989;39(9):1246–50.

    Article  CAS  PubMed  Google Scholar 

  18. Minematsu K, Yamaguchi T, Omae T. “Spectacular shrinking deficit”: rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology. 1992;42(1):157–62.

    Article  CAS  PubMed  Google Scholar 

  19. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003;22(2):118–23.

    Article  PubMed  Google Scholar 

  20. Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke. 2004;35(7):1769–75.

    Article  PubMed  Google Scholar 

  21. Helgason CM. Cardioembolic stroke: topography and pathogenesis. Cerebrovasc Brain Metab Rev. 1992;4(1):28–58.

    CAS  PubMed  Google Scholar 

  22. Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.

    Article  PubMed  Google Scholar 

  23. Alhadramy O, Jeerakathil TJ, Majumdar SR, Najjar E, Choy J, Saqqur M. Prevalence and predictors of paroxysmal atrial fibrillation on Holter monitor in patients with stroke or transient ischemic attack. Stroke. 2010;41(11):2596–600.

    Article  PubMed  Google Scholar 

  24. Stahrenberg R, Weber-Krüger M, Seegers J, Edelmann F, Lahno R, Haase B, et al. Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke. 2010;41(12):2884–8.

    Article  PubMed  Google Scholar 

  25. Elijovich L, Josephson SA, Fung GL, Smith WS. Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis. 2009;18(3):185–9.

    Article  PubMed  Google Scholar 

  26. Tayal AH, Tian M, Kelly KM, Jones SC, Wright DG, Singh D, et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology. 2008;71(21):1696–701.

    Article  CAS  PubMed  Google Scholar 

  27. Gaillard N, Deltour S, Vilotijevic B, Hornych A, Crozier S, Leger A, et al. Detection of paroxysmal atrial fibrillation with transtelephonic EKG in TIA or stroke patients. Neurology. 2010;74(21):1666–70.

    Article  CAS  PubMed  Google Scholar 

  28. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45(2):520–6.

    Article  CAS  PubMed  Google Scholar 

  29. Culebras A, Messe SR, Chaturvedi S, Kase CS, Gronseth G. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82(8):716–24.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Bernstein, Richard A, Sanna, Tommaso, Diener H-C, Passman RS, Di Lazzaro V, Morillo C, et al. Cryptogenic Stroke and Underlying Atrial Fibrillation (CRYSTAL AF). San Diego, CA, USA; 2014.

    Google Scholar 

  31. Diener H-C. To monitor or to not monitor for paroxysmal atrial fibrillation after transient ischemic attack or stroke: this is the question. Stroke. 2014;45(2):355–6.

    Article  PubMed  Google Scholar 

  32. Montaner J, Perea-Gainza M, Delgado P, Ribó M, Chacón P, Rosell A, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke. 2008;39(8):2280–7.

    Article  CAS  PubMed  Google Scholar 

  33. Shibazaki K, Kimura K, Iguchi Y, Okada Y, Inoue T. Plasma brain natriuretic peptide can be a biological marker to distinguish cardioembolic stroke from other stroke types in acute ischemic stroke. Intern Med. 2009;48(5):259–64.

    Article  PubMed  Google Scholar 

  34. Morris JG, Singh S, Fisher M. Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good? Stroke. 2010;41(12):2985–90.

    Article  PubMed  Google Scholar 

  35. Harloff A, Handke M, Reinhard M, Geibel A, Hetzel A. Therapeutic strategies after examination by transesophageal echocardiography in 503 patients with ischemic stroke. Stroke. 2006;37(3):859–64.

    Article  PubMed  Google Scholar 

  36. Douglas PS, Khandheria B, Stainback RF, Weissman NJ, Brindis RG, Patel MR, et al. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Coll Cardiol. 2007;50(2):187–204.

    Article  PubMed  Google Scholar 

  37. Walpot J, Pasteuning WH, Hoevenaar M, den Braber J, Sorgedrager J, Oostdijk-de Rijke M, et al. Transesophageal echocardiography in patients with cryptogenic stroke: does it alter their management? A 3-year retrospective study in a single non-referral centre. Acta Clin Belg. 2006;61(5):243–8.

    Article  CAS  PubMed  Google Scholar 

  38. De Abreu TT, Mateus S, Carreteiro C, Correia J. Therapeutic implications of transesophageal echocardiography after transthoracic echocardiography on acute stroke patients. Vasc Health Risk Manag. 2008;4(1):167–72.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Shin H-Y, Jeong I-H, Kang C-K, Shin D-J, Park H-M, Park K-H, et al. Relation between left atrial enlargement and stroke subtypes in acute ischemic stroke patients. J Cerebrovasc Endovasc Neurosurg. 2013;15(3):131–6.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Marriott K, Manins V, Forshaw A, Wright J, Pascoe R. Detection of right-to-left atrial communication using agitated saline contrast imaging: experience with 1162 patients and recommendations for echocardiography. J Am Soc Echocardiogr. 2013;26(1):96–102.

    Article  PubMed  Google Scholar 

  41. Tong DC, Bolger A, Albers GW. Incidence of transcranial Doppler-detected cerebral microemboli in patients referred for echocardiography. Stroke. 1994;25(11):2138–41.

    Article  CAS  PubMed  Google Scholar 

  42. Albert A, Müller HR, Hetzel A. Optimized transcranial Doppler technique for the diagnosis of cardiac right-to-left shunts. J Neuroimaging. 1997;7(3):159–63.

    CAS  PubMed  Google Scholar 

  43. Schwarze JJ, Sander D, Kukla C, Wittich I, Babikian VL, Klingelhöfer J. Methodological parameters influence the detection of right-to-left shunts by contrast transcranial Doppler ultrasonography. Stroke. 1999;30(6):1234–9.

    Article  CAS  PubMed  Google Scholar 

  44. Droste DW, Lakemeier S, Wichter T, Stypmann J, Dittrich R, Ritter M, et al. Optimizing the technique of contrast transcranial Doppler ultrasound in the detection of right-to-left shunts. Stroke. 2002;33(9):2211–6.

    Article  PubMed  Google Scholar 

  45. Hendel RC, Patel MR, Kramer CM, Poon M, Hendel RC, Carr JC, et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol. 2006;48(7):1475–97.

    Article  PubMed  Google Scholar 

  46. Rustemli A, Bhatti TK, Wolff SD. Evaluating cardiac sources of embolic stroke with MRI. Echocardiography. 2007;24(3):301–8. discussion 308.

    Article  PubMed  Google Scholar 

  47. Freeman WD, Aguilar MI. Stroke prevention in atrial fibrillation and other major cardiac sources of embolism. Neurol Clin. 2008;26(4):1129–60. x–xi.

    Article  PubMed  Google Scholar 

  48. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25.

    Article  PubMed  Google Scholar 

  49. European Heart Rhythm Association, Heart Rhythm Society, Fuster V, Rydén LE, Cannom DS, Crijns HJ, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854–906.

    Article  Google Scholar 

  50. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155(5):469–73.

    Article  CAS  PubMed  Google Scholar 

  51. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–12.

    Article  CAS  Google Scholar 

  52. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol. 2007;50(22):2156–61.

    Article  CAS  PubMed  Google Scholar 

  53. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.

    Article  CAS  PubMed  Google Scholar 

  54. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8.

    Article  CAS  PubMed  Google Scholar 

  55. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323(22):1505–11.

    Google Scholar 

  56. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84(2):527–39.

    Article  Google Scholar 

  57. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA. 1998;279(16):1273–7.

    Google Scholar 

  58. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327(20):1406–12.

    Article  CAS  PubMed  Google Scholar 

  59. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1(8631):175–9.

    Article  CAS  PubMed  Google Scholar 

  60. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18(2):349–55.

    Article  CAS  PubMed  Google Scholar 

  61. Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med. 2000;109(1):45–51.

    Article  CAS  PubMed  Google Scholar 

  62. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70.

    Article  CAS  PubMed  Google Scholar 

  63. Aakre CA, McLeod CJ, Cha SS, Tsang TSM, Lip GYH, Gersh BJ. Comparison of clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation. Stroke. 2013;45(2):426–31.

    Article  PubMed  Google Scholar 

  64. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.

    Article  PubMed  Google Scholar 

  65. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449–57.

    Google Scholar 

  66. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA. 1999;281(19):1830–5.

    Article  CAS  PubMed  Google Scholar 

  67. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114(5 Suppl):579S–89.

    Article  CAS  PubMed  Google Scholar 

  68. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.

    Article  PubMed  Google Scholar 

  69. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342(8882):1255–62.

    Google Scholar 

  70. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492–501.

    Article  CAS  PubMed  Google Scholar 

  71. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;(4):CD001925.

    Google Scholar 

  72. Gulløv AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158(14):1513–21.

    Article  PubMed  Google Scholar 

  73. Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319(7215):958–64.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Vemmos KN, Tsivgoulis G, Spengos K, Manios E, Xinos K, Vassilopoulou S, et al. Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation–a randomized pilot trial comparing adjusted-dose and fixed low-dose coumadin with aspirin. Eur J Intern Med. 2006;17(1):48–52.

    Article  CAS  PubMed  Google Scholar 

  75. Hu D, Zhang H, Sun Y, Jiang L. Antithrombotic Therapy in Atrial Fibrillation Study Group. [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. Zhonghua Xin Xue Guan Bing Za Zhi. 2006;34(4):295–8.

    CAS  PubMed  Google Scholar 

  76. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007;36(2):151–6.

    Article  PubMed  Google Scholar 

  77. Pérez-Gómez F, Alegría E, Berjón J, Iriarte JA, Zumalde J, Salvador A, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44(8):1557–66.

    Article  PubMed  CAS  Google Scholar 

  78. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348(9028):633–8.

    Article  Google Scholar 

  79. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):483S–512.

    Article  CAS  PubMed  Google Scholar 

  80. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–78.

    Article  Google Scholar 

  81. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.

    Article  CAS  PubMed  Google Scholar 

  82. Seet RCS, Rabinstein AA, Christianson TJH, Petty GW, Brown Jr RD. Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study. J Stroke Cerebrovasc Dis. 2013;22(4):561–9.

    Article  PubMed Central  PubMed  Google Scholar 

  83. Stroke Prevention In Atrial Fibrillation Investigators. The stroke prevention in atrial fibrillation III study: rationale, design, and patient features. J Stroke Cerebrovasc Dis. 1997;6(5):341–53.

    Article  Google Scholar 

  84. Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G, Lecompte T, et al. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). Cerebrovasc Dis. 2001;12(3):245–52.

    Article  CAS  PubMed  Google Scholar 

  85. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5):297–305.

    Article  PubMed Central  PubMed  Google Scholar 

  86. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(11):2599–604.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  87. Eikelboom JW, Connolly SJ, Gao P, Paolasso E, De Caterina R, Husted S, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012;21(6):429–35.

    Article  PubMed  Google Scholar 

  88. Olesen JB, Lip GYH, Kamper A-L, Hommel K, Køber L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625–35.

    Article  CAS  PubMed  Google Scholar 

  89. Akins PT, Feldman HA, Zoble RG, Newman D, Spitzer SG, Diener H-C, et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke. 2007;38(3):874–80.

    Article  CAS  PubMed  Google Scholar 

  90. Albers GW, Diener H-C, Frison L, Grind M, Nevinson M, Partridge S, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293(6):690–8.

    Article  PubMed  Google Scholar 

  91. Olsson SB. Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362(9397):1691–8.

    Article  CAS  PubMed  Google Scholar 

  92. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

    Article  CAS  PubMed  Google Scholar 

  93. Boehringer Ingelheim Pharmaceuticals, Inc. Dabigatran (Pradaxa) [Package Insert]. 2010.

    Google Scholar 

  94. Press Announcements > FDA approves Pradaxa to prevent stroke in people with atrial fibrillation [Internet]. [cited 2014 Mar 5]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm

  95. Medi C, Hankey GJ, Freedman SB. Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke. 2010;41(11):2705–13.

    Article  PubMed  Google Scholar 

  96. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.

    Article  CAS  PubMed  Google Scholar 

  97. Kadokura T, Kashiwa M, Groenendaal D, Heeringa M, Mol R, Verheggen F, et al. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects. Biopharm Drug Dispos. 2013;34(8):431–41.

    Article  CAS  PubMed  Google Scholar 

  98. Connolly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, Sinha U, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J. 2013;34(20):1498–505.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  99. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.

    Article  CAS  PubMed  Google Scholar 

  100. Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.

    Article  CAS  PubMed  Google Scholar 

  101. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

    Article  CAS  PubMed  Google Scholar 

  102. Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation. 2009;120(12):1029–35. 2 p following 1035.

    Article  CAS  PubMed  Google Scholar 

  103. Harrington AR, Armstrong EP, Nolan Jr PE, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676–81.

    Article  PubMed  Google Scholar 

  104. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.

    Article  PubMed  Google Scholar 

  105. Freeman WD, Aguilar MI, Weitz J. Risk of intracerebral bleeding in patients treated with anticoagulants [Internet]. [cited 2014 Mar 5]. Available from: http://www.uptodate.com/contents/risk-of-intracerebral-bleeding-in-patients-treated-with-anticoagulants?source=search_result&search=risk+of+intracerebral+hemorrhage+in+patients+treated+with+warfarin&selectedTitle=1%7E150

  106. Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg. 1999;118(5):833–40.

    Article  CAS  PubMed  Google Scholar 

  107. Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J. 2005;150(2):288–93.

    Article  PubMed  Google Scholar 

  108. Whitlock RP, Vincent J, Blackall MH, Hirsh J, Fremes S, Novick R, et al. Left Atrial Appendage Occlusion Study II (LAAOS II). Can J Cardiol. 2013;29(11):1443–7.

    Article  PubMed  Google Scholar 

  109. Whitlock R, Healey J, Vincent J, Brady K, Teoh K, Royse A, et al. Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. Ann Cardiothorac Surg. 2014;3(1):45–54.

    PubMed Central  PubMed  Google Scholar 

  110. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534–42.

    Article  CAS  PubMed  Google Scholar 

  111. Reddy VY, Möbius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61(25):2551–6.

    Article  PubMed  Google Scholar 

  112. Block PC, Burstein S, Casale PN, Kramer PH, Teirstein P, Williams DO, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv. 2009;2(7):594–600.

    Article  PubMed  Google Scholar 

  113. Bayard Y-L, Omran H, Neuzil P, Thuesen L, Pichler M, Rowland E, et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention. 2010;6(2):220–6.

    Article  PubMed  Google Scholar 

  114. Horstmann S, Zugck C, Krumsdorf U, Rizos T, Rauch G, Geis N, et al. Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage. Neurology. 2014;82(2):135–8.

    Article  PubMed Central  PubMed  Google Scholar 

  115. Crandall MA, Bradley DJ, Packer DL, Asirvatham SJ. Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies. Mayo Clin Proc. 2009;84(7):643–62.

    Article  PubMed Central  PubMed  Google Scholar 

  116. Cruz-Gonzalez I, Yan BP, Lam Y-Y. Left atrial appendage exclusion: state-of-the-art. Catheter Cardiovasc Interv. 2010;75(5):806–13.

    Article  PubMed  Google Scholar 

  117. Covidien Subsidiary Hit by Milestone Payment Lawsuit | Qmed [Internet]. [cited 2014 Mar 6]. Available from: http://www.qmed.com/news/covidien-subsidiary-hit-milestone-payment-lawsuit

  118. Search of: left atrial occlusion - List Results - ClinicalTrials.gov [Internet]. [cited 2014 Mar 5]. Available from: http://clinicaltrials.gov/ct2/results?term=left+atrial+occlusion

  119. Witt BJ, Brown Jr RD, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA, et al. Ischemic stroke after heart failure: a community-based study. Am Heart J. 2006;152(1):102–9.

    Article  PubMed  Google Scholar 

  120. Assessment of short-anticoagulant administration after cardiac infarction. Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. Br Med J. 1969;1(5640):335–42.

    Google Scholar 

  121. Anticoagulants in acute myocardial infarction. Results of a cooperative clinical trial. JAMA. 1973;225(7):724–9.

    Google Scholar 

  122. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet. 1994;343(8896):499–503.

    Google Scholar 

  123. Cairns JA, Théroux P, Lewis Jr HD, Ezekowitz M, Meade TW, Sutton GC. Antithrombotic agents in coronary artery disease. Chest. 1998;114(5 Suppl):611S–33.

    Article  CAS  PubMed  Google Scholar 

  124. Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient’s age, sex, and severity of infarction. JAMA. 1972;222(5):541–8.

    Article  CAS  PubMed  Google Scholar 

  125. Young J. Chronic heart failure management. In: Topol EJ, editor. Comprehensive cardiovascular medicine. Philadelphia, PA: Lippincott-Raven; 1998.

    Google Scholar 

  126. Di Tullio MR, Homma S. Mechanisms of cardioembolic stroke. Curr Cardiol Rep. 2002;4(2):141–8.

    Article  PubMed  Google Scholar 

  127. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, et al. Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdam Study. Eur Heart J. 1999;20(6):447–55.

    Article  CAS  PubMed  Google Scholar 

  128. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336(4):251–7.

    Article  CAS  PubMed  Google Scholar 

  129. ANDERSON GM, HULL E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J. 1950;39(5):697–702.

    Article  CAS  PubMed  Google Scholar 

  130. GRIFFITH GC, STRAGNELL R, LEVINSON DC, MOORE FJ, WARE AG. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med. 1952;37(5):867–87.

    Article  CAS  PubMed  Google Scholar 

  131. HARVEY WP, FINCH CA. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med. 1950;242(6):208–11.

    Article  CAS  PubMed  Google Scholar 

  132. Georgiadis D, Sievert M, Cencetti S, Uhlmann F, Krivokuca M, Zierz S, et al. Cerebrovascular reactivity is impaired in patients with cardiac failure. Eur Heart J. 2000;21(5):407–13.

    Article  CAS  PubMed  Google Scholar 

  133. Alves TCTF, Rays J, Fráguas Jr R, Wajngarten M, Meneghetti JC, Prando S, et al. Localized cerebral blood flow reductions in patients with heart failure: a study using 99mTc-HMPAO SPECT. J Neuroimaging. 2005;15(2):150–6.

    Article  PubMed  Google Scholar 

  134. Hays AG, Sacco RL, Rundek T, Sciacca RR, Jin Z, Liu R, et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke. 2006;37(7):1715–9.

    Article  PubMed Central  PubMed  Google Scholar 

  135. Freudenberger RS, Hellkamp AS, Halperin JL, Poole J, Anderson J, Johnson G, et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2007;115(20):2637–41.

    Article  PubMed  Google Scholar 

  136. Koniaris LS, Goldhaber SZ. Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol. 1998;31(4):745–8.

    Article  CAS  PubMed  Google Scholar 

  137. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol. 1997;29(5):1074–80.

    Article  CAS  PubMed  Google Scholar 

  138. Cleland JGF, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148(1):157–64.

    Article  CAS  PubMed  Google Scholar 

  139. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK. HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail. 2006;8(4):428–32.

    Article  CAS  PubMed  Google Scholar 

  140. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 Suppl):VI94–101.

    CAS  PubMed  Google Scholar 

  141. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47(3):525–31.

    Article  CAS  PubMed  Google Scholar 

  142. Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail. 2004;10(2):101–12.

    Article  CAS  PubMed  Google Scholar 

  143. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JGF, Ezekowitz M, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009;119(12):1616–24.

    Article  CAS  PubMed  Google Scholar 

  144. Homma S, Thompson JLP, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366(20):1859–69.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  145. Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia. 2008;28(5):531–40.

    Article  CAS  PubMed  Google Scholar 

  146. Maisel WH, Laskey WK. Patent foramen ovale closure devices: moving beyond equipoise. JAMA. 2005;294(3):366–9.

    Article  CAS  PubMed  Google Scholar 

  147. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105(22):2625–31.

    Article  PubMed  Google Scholar 

  148. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366(11):991–9.

    Article  CAS  PubMed  Google Scholar 

  149. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Study design of the CLOSURE I Trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Stroke. 2010;41(12):2872–83.

    Article  PubMed  Google Scholar 

  150. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368(12):1092–100.

    Article  CAS  PubMed  Google Scholar 

  151. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368(12):1083–91.

    Article  CAS  PubMed  Google Scholar 

  152. Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence - Full Text View - ClinicalTrials.gov [Internet]. [cited 2014 Mar 5]. Available from: http://clinicaltrials.gov/ct2/show/NCT00562289

  153. GORE® HELEX® Septal Occluder/GORE® Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study - Full Text View - ClinicalTrials.gov [Internet]. [cited 2014 Mar 6]. Available from: http://clinicaltrials.gov/ct2/show/NCT00738894?term=NCT00738894&rank=1

  154. Itoh T, Matsumoto M, Handa N, Maeda H, Hougaku H, Tsukamoto Y, et al. Paradoxical embolism as a cause of ischemic stroke of uncertain etiology. A transcranial Doppler sonographic study. Stroke. 1994;25(4):771–5.

    Article  CAS  PubMed  Google Scholar 

  155. Myers PO, Bounameaux H, Panos A, Lerch R, Kalangos A. Impending paradoxical embolism: systematic review of prognostic factors and treatment. Chest. 2010;137(1):164–70.

    Article  PubMed  Google Scholar 

  156. Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med. 1994;331(22):1474–9.

    Article  CAS  PubMed  Google Scholar 

  157. Fujimoto S, Yasaka M, Otsubo R, Oe H, Nagatsuka K, Minematsu K. Aortic arch atherosclerotic lesions and the recurrence of ischemic stroke. Stroke. 2004;35(6):1426–9.

    Article  PubMed  Google Scholar 

  158. Tunick PA, Nayar AC, Goodkin GM, Mirchandani S, Francescone S, Rosenzweig BP, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol. 2002;90(12):1320–5.

    Article  PubMed  Google Scholar 

  159. Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J Am Coll Cardiol. 1998;31(1):134–8.

    Article  CAS  PubMed  Google Scholar 

  160. American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease), Society of Cardiovascular Anesthesiologists, Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2006;48(3):e1–148.

    Article  Google Scholar 

  161. Mills P, Leech G, Davies M, Leathan A. The natural history of a non-stenotic bicuspid aortic valve. Br Heart J. 1978;40(9):951–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  162. Salem DN, Levine HJ, Pauker SG, Eckman MH, Daudelin DH. Antithrombotic therapy in valvular heart disease. Chest. 1998;114(5 Suppl):590S–601.

    Article  CAS  PubMed  Google Scholar 

  163. Salgado A, Furlan A, Salcedo E. Risk of stroke in patients with congenital bicuspid valve. J Stroke Cerebrovasc Dis. 1991;1:61–3.

    Article  CAS  PubMed  Google Scholar 

  164. Stein PD, Dalen JE, Goldman S, Théroux P. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest. 1998;114(5 Suppl):658S–65.

    Article  CAS  PubMed  Google Scholar 

  165. Davidson CJ, Skelton TN, Kisslo KB, Kong Y, Peter RH, Simonton CA, et al. The risk for systemic embolization associated with percutaneous balloon valvuloplasty in adults. A prospective comprehensive evaluation. Ann Intern Med. 1988;108(4):557–60.

    Article  CAS  PubMed  Google Scholar 

  166. Pullicino P, Thompson JLP, Barton B, Levin B, Graham S, Freudenberger RS, et al. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail. 2006;12(1):39–46.

    Article  CAS  PubMed  Google Scholar 

  167. Petty GW, Orencia AJ, Khandheria BK, Whisnant JP. A population-based study of stroke in the setting of mitral valve prolapse: risk factors and infarct subtype classification. Mayo Clin Proc. 1994;69(7):632–4.

    Article  CAS  PubMed  Google Scholar 

  168. Wolf PA, Sila CA. Cerebral ischemia with mitral valve prolapse. Am Heart J. 1987;113(5):1308–15.

    Article  CAS  PubMed  Google Scholar 

  169. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–14.

    Article  CAS  PubMed  Google Scholar 

  170. Stein PD, Alpert JS, Dalen JE, Horstkotte D, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 1998;114(5 Suppl):602S–10.

    Article  CAS  PubMed  Google Scholar 

  171. Kizer JR, Devereux RB. Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N Engl J Med. 2005;353(22):2361–72.

    Article  CAS  PubMed  Google Scholar 

  172. Landing B, Farber S. Tumors of the cardiovascular system. Atlas of tumor pathology. 1st ed. Washington, DC: Armed Forces Institute of Pathology; 1956.

    Google Scholar 

  173. Reynen K. Frequency of primary tumors of the heart. Am J Cardiol. 1996;77(1):107.

    Article  CAS  PubMed  Google Scholar 

  174. Aziz F, Baciewicz Jr FA. Lambl’s excrescences: review and recommendations. Tex Heart Inst J. 2007;34(3):366–8.

    PubMed Central  PubMed  Google Scholar 

  175. Lopez JA, Ross RS, Fishbein MC, Siegel RJ. Nonbacterial thrombotic endocarditis: a review. Am Heart J. 1987;113(3):773–84.

    Article  CAS  PubMed  Google Scholar 

  176. Dismukes WE. Management of infective endocarditis. Cardiovasc Clin. 1981;11(3):189–208.

    CAS  PubMed  Google Scholar 

  177. Fleming HA. General principles of the treatment of infective endocarditis. J Antimicrob Chemother. 1987;20(Suppl A):143–5.

    Article  PubMed  Google Scholar 

  178. Hart RG, Foster JW, Luther MF, Kanter MC. Stroke in infective endocarditis. Stroke. 1990;21(5):695–700.

    Article  CAS  PubMed  Google Scholar 

  179. Prabhakaran S. Neurologic complications of endocarditis. Continuum Lifelong Learning in Neurology. 2008;14:53–73.

    Article  Google Scholar 

  180. Robbins MJ, Eisenberg ES, Frishman WH. Infective endocarditis: a pathophysiologic approach to therapy. Cardiol Clin. 1987;5(4):545–62.

    CAS  PubMed  Google Scholar 

  181. Salgado AV, Furlan AJ, Keys TF, Nichols TR, Beck GJ. Neurologic complications of endocarditis: a 12-year experience. Neurology. 1989;39(2 Pt 1):173–8.

    Article  CAS  PubMed  Google Scholar 

  182. Kang D-H, Kim Y-J, Kim S-H, Sun BJ, Kim D-H, Yun S-C, et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med. 2012;366(26):2466–73.

    Article  CAS  PubMed  Google Scholar 

  183. Reynen K. Cardiac myxomas. N Engl J Med. 1995;333(24):1610–7.

    Article  CAS  PubMed  Google Scholar 

  184. Sastre-Garriga J, Molina C, Montaner J, Mauleón A, Pujadas F, Codina A, et al. Mitral papillary fibroelastoma as a cause of cardiogenic embolic stroke: report of two cases and review of the literature. Eur J Neurol. 2000;7(4):449–53.

    Article  CAS  PubMed  Google Scholar 

  185. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343(8899):687–91.

    Google Scholar 

  186. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13.

    Article  CAS  PubMed  Google Scholar 

  187. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatr. 1991;54(12):1044–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  188. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J. 1999;138(1 Pt 1):137–43.

    Article  CAS  PubMed  Google Scholar 

  189. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37(2):447–51.

    Article  CAS  PubMed  Google Scholar 

  190. Edvardsson N, Juul-Möller S, Omblus R, Pehrsson K. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med. 2003;254(1):95–101.

    Article  CAS  PubMed  Google Scholar 

  191. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke. 1997;28(5):1015–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Mayo Clinic Florida, 4500 San Pablo Road S, Jacksonville, FL, 32224, USA

    Mark N. Rubin M.D. & W. David Freeman M.D.

  2. Department of Neurology, Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA

    Maria I. Aguilar M.D.

Authors
  1. Mark N. Rubin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. David Freeman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria I. Aguilar M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark N. Rubin M.D. .

Editor information

Editors and Affiliations

  1. Admiral Pihl Professor and Chairman of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA

    Bruce Ovbiagele

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Rubin, M.N., Freeman, W.D., Aguilar, M.I. (2016). Secondary Prevention After Cardioembolic Stroke. In: Ovbiagele, B. (eds) Ischemic Stroke Therapeutics. Springer, Cham. https://doi.org/10.1007/978-3-319-17750-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-17750-2_12

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-17749-6

  • Online ISBN: 978-3-319-17750-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation